Skip to main content

Table 1 Patient demography and treatment

From: Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis

Patient no.

Diagnosis

Treatment duration at second biopsy (months)

Cumulative prednisolone dose at second biopsy (mg)

Other immunosuppressive agents at second biopsy

ANA (+/neg) and pattern

Autoantibodies detected in line immunoassay

1

DM

8

6005

MTX

+, granular

neg

2

DM

5

5210

AZA

+, granular

neg

3

DM

7

7875

None

+, granular

neg

4

DMa

10

4778

MTX

+, granular

anti-Ro-52, anti-Ro-60, anti-LA

5

DM

11

7179

AZA

+, granular

neg

6

DM

9

8668

AZA

neg

anti-Ro-52

7

DMb

4

3935

None

+, granular

anti-Ro-52, anti-PL7

8

DMb

8

NA

AZA, CsA

+, granular

anti-Ro-52

9

PM

6

5250

MTX

+, granular and homogenous

anti-Ro-52, anti-SRP

10

PM

12

9090

AZA

+, granular

neg

11

PM

11

9013

MTX, AZA

NA

NA

12

PMb

16

6775

AZA

neg

anti-Mi2

13

PMb

4

5525

CYC

neg

anti-Jo-1, anti-Ro-52

14

PMb

6

1360

None

neg

neg

15

PM

9

3702

AZA

neg

anti-Ro-52, anti-Ro-60

16

PM

8

8435

AZA

+, granular

anti-Ro-52

  1. aAdditional diagnosis Sjögren's syndrome.
  2. bDiagnosis probable
  3. + positive, ANA anti-nuclear antibodies, AZA azathioprine, CsA cyclosporine A, CYC cyclophosphamide, DM dermatomyositis, MTX methotrexate, NA not available, neg negative, PM polymyositis